This week's FDA advisory committee meeting on rosiglitazone (Avandia) drew back the curtain on the agency's internal politics but left its final decision shrouded in uncertainty.Note: "given the inconclusive and flawed evidence available..."
On Wednesday, the panel voted 20-12 in favor of rosiglitazone's continued availability on the market, although 17 of the 20 supporters called for tougher warnings on the drug's label.
The inconclusive voting came as little surprise given the inconclusive and flawed evidence available, noted endocrinologist David Nathan, MD, of Massachusetts General Hospital in Boston.
Really, don't you think you would be a lot smarter to lose the pounds than deal with drugs where marketability is based on "inconclusive and flawed evidence"?
Do you think this is the only med out there like that?
Posts
No comments:
Post a Comment